Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

“One pill, once daily”: what clinicians need to know about Atripla™

Authors Clay PG, Taylor TAH, Glaros AG, McRae M, Williams C, McCandless D, Oelklaus M

Published 11 April 2008 Volume 2008:4(2) Pages 291—302


Patrick G Clay1,2, Tracey AH Taylor1, Alan G Glaros3, MaryPeace McRae1, Charlott Williams2, Don McCandless1, Maurice Oelklaus4

1Department of Pharmacology/Microbiology; 2Department of Clinical Research; 3Division of Basic Sciences; 4College of Medicine, Kansas City University of Medicine and Biosciences, Kansas City, MO, USA

Abstract: As the number of persons chronically prescribed antiretrovirals has grown and the realization that antiretrovirals are required to be continued for life, pharmaceutical manufacturers have developed new classes of agents, improved the pharmacokinetics of marketed products through dosing reformulations, and in an effort to maximize success with respect to adherence, compiled into a single dosing unit all necessary elements for an antiretroviral regimen. Atripla™ represents the first ever fixed-dose combination antiretroviral available. This article reviews currently available data on this agent, the impact of resistance on clinical use and implementation, as well as extensive descriptions of the pharmacokinetics, adverse effects and drug-interactions warranting consideration. Whether beginning in a naïve patient or switching from other regimens for tolerability issues, Atripla™ represents a viable option. Its demonstrated advantages with respect to lipid and hematologic parameters and equivalent incidence of renal toxicity are tempered by the findings of bone mineral density decreases, however. Combining multiple mechanisms of action in a single dosing unit appears to improve efficacy, increase the likelihood for adherence and maintain viral suppression compared to administering these agents independently. It is suggested other pharmaceutical companies assess the potential to replicate this for the remaining antiretrovirals.

Keywords: Atripla™, antiretrovirals, HIV

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]